Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)

Phase 2 Completed 48 enrolled Menoufia University

NaSingle-groupOpen-labelTreatment

Summary

In this study, the investigators designed a treatment regimen including the most active agents in pancreatic cancer which are gemcitabine and fluorouracil to be tested as a first line treatment. This regimen is expected to be less toxic than FOLFIRINOX and aiming at better outcomes.

Timeline

Start: 2021-02-20
Primary completion: 2022-07-09
Completion: 2022-07-09

Publications

Background Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	fluorouracil	Small molecule	400 mg/m2	Intravenous
Subject	fluorouracil	Small molecule	2000 mg/m2	Intravenous
Background	Leucovorin	Small molecule	400 mg/m2	Intravenous

Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)

Summary

Timeline

Publications

Drugs

Indications